All posts by imreal

Kno2 Recognized By HHS As An Inaugural QHIN Applicant Under TEFCA


News Image

“By becoming a QHIN, Kno2 can leverage its expertise and capabilities to help ensure TEFCA is successful, and providers, patients and health plans have seamless access to the right patient health information when and where it is needed.”

Kno2®, the company leading the future of healthcare communication, announced today that its application to be a designated Qualified Health Information Network (QHIN) under the Trusted Exchange Framework and Common Agreement (TEFCA), has been accepted by The Sequoia Project as the Recognized Coordinating Entity.

Kno2 was invited by Health and Human Services (HHS) to attend a TEFCA recognition event today in Washington, DC to commemorate a major interoperability milestone. VP of interoperability, Matt Becker represented Kno2 as a recipient of a “Certificate of Recognition” for being an inaugural QHIN applicant to proceed to Phase 3: Pre-production Testing Process and Project Plan Completion.

This application approval brings Kno2 one step closer to potentially becoming a QHIN. If designated, the company will drive participation through its extensive portfolio of existing partners in addition to providing organizations of all sizes interested in participating in TEFCA with access to the most expansive and comprehensive communication network available in healthcare today. This broad connectivity would be facilitated via Kno2’s Communication API.

“Our team is eager to support America’s urgent need for nationwide interoperability and to help improve patient outcomes, address provider burnout, and eradicate financial burdens across healthcare today,” said Therasa Bell, co-founder, president, and chief technology officer at Kno2. “By becoming a QHIN, Kno2 can leverage its expertise and capabilities to help ensure TEFCA is successful, and providers, patients and health plans have seamless access to the right patient health information when and where it is needed.”

At a recent event in Las Vegas, Micky Tripathi, the national coordinator for health information technology at HHS, thanked Kno2 for stepping up and applying for QHIN designation. “We recognize it is voluntary and requires significant effort to meet the qualifications for QHIN designation. There are only a handful of organizations who have made it to step three in the application process, committing to be fully tested and validated within 12 months from their approved application to ensure successful QHIN-to-QHIN exchange.”

“For health interoperability to truly work, everyone across the healthcare ecosystem must be involved,” says Jon Elwell, CEO of Kno2. “Kno2’s current network is already connected to critical sectors of care from post-acute, therapies, home care to EMS. We intend to broaden our efforts to assist the on-boarding of digital health platforms and other sectors of healthcare upon successful designation.”

Additional Resources:

Kno2’s Pursuit for QHIN Designation

QHIN Video Interview with Kno2’s Therasa Bell

About Kno2

The Kno2 network enables the secure, effortless and maximized exchange of patient information across patients, providers, payers and IT vendors. We are empowering healthcare to finally realize the true potential of interoperability by unleashing connectivity everywhere through a simple to use Communication API and robust tools for any business. With industry disrupting economics and our passion to include the underserved, Kno2 is democratizing healthcare communications and defining the new connected future of healthcare. With a single connection to Kno2, anyone can quickly gain access to a powerful network of connected networks, EHRs, HIEs, organizations, technologies and interoperability frameworks that gives the freedom to easily communicate with all. To learn more, visit http://www.kno2.com

Share article on social media or email:

West Palm Beach Tummy Tuck and Plastic Surgeon, Precision Medical Specialists, is Recognized as a 2023 Top Patient Rated Doctor by Find Local Doctors


News Image

“It is always an honor to receive this award, as we consistently strive to provide patients with the very best,” says Dr. Steven Rueda.

Providing the elite skills of a plastic surgeon, general surgeon, dermatologist and full medical team on-site, Precision Medical Specialists is an advanced medical facility in West Palm Beach, Florida. Find Local Doctors is an online directory that helps users easily connect with the best physicians in their area. They recognize providers who have earned numerous exceptional reviews and five-star ratings from patients across multiple online sources. At Precision Medical Specialists, the team understands that the skin, face and body are all connected for form and function and have created an inclusive, comprehensive medical center to address multiple conditions. They offer the talent and experience of three renowned medical professionals, providing plastic surgery, skin, vein and hand procedures, all under one roof. Dr. Steven Rueda is Precision Medical Specialists’ resident plastic surgeon and hand specialist, Dr. Mario Rueda is a general surgeon and vascular expert and Dr. Katherine Chiang is a highly respected dermatologist. All three have achieved extensive accolades in their respective fields and work together to provide patients with exceptional care. The plastic surgery services offered at this practice include facial plastic surgery, breast augmentation, abdominoplasty, body contouring and non-surgical cosmetic treatments. The team also provides hand, finger and wrist treatments and surgery, vein disease treatment and surgery, general and cosmetic dermatology services and the very best in skin cancer treatment. The center presents several benefits over other clinics in the West Palm Beach, FL, area, including state-of-the-art surgical suites, cutting-edge medical equipment, extensive patient education and a dedicated support team on staff.

“It is always an honor to receive this award, as we consistently strive to provide patients with the very best,” says Dr. Steven Rueda.

More about Precision Medical Specialists:

Precision Medical Specialists in Wellington, FL, is a unique practice that offers plastic surgery, dermatology, hand surgery and vein disease treatment to address a wide spectrum of medical needs all under one roof. The surgeons and doctors at Precision Medical Specialists offer the credentials, experience and training that patients deserve. For more information, please contact the clinic, located at 3319 State Road 7 Suite 105 in Wellington, FL, by calling (561) 557-3115 or visiting http://www.precisionmds.com.

Share article on social media or email:

The Weight Loss Surgery Center of LA Founder Dr. David Davtyan Points to Recently Completed 40-Year Study on Weight Loss Surgery Confirming Benefits of Bariatric Surgery


News Image

“The take-home message of this study indicates that people suffering from obesity can extend their lives and reduce their mortality, particularly from diabetes, cancer, and cardiovascular disease with the help of bariatric surgery,” says Dr. David Davtyan.

According to the recent U.S News and World Report article, “40-Year Study Finds Weight-Loss Surgery Extending Life Spans,” a brand-new study published in the January edition of the Obesity medical journal, shows that weight-loss surgery could set a person’s health and longevity on a different path. In the research, patients were followed for up to 40 years after they had one of four types of weight loss surgery (bariatric surgery), sleeve gastrectomy, laparoscopic adjustable gastric banding (commonly known as Lap-Band), Roux-en-Y gastric bypass, and biliopancreatic diversion with duodenal switch (BPDS). Researchers found that these patients had significant reductions in death rates from all causes (16% lower) compared to obese patients who did not have surgery. For heart disease, it was 29% lower, cancer deaths dropped by 43%, and it was down a full 72% for diabetes. The report concluded that having surgery is beneficial overall in extending life, and patients should probably have it sooner rather than later to prevent other diseases. At the Weight Loss Surgery Center of Los Angeles, a prominent weight loss center located in Beverly Hills, Dr. David Davtyan performs the surgical procedures listed in the study and more to help his patients win their battle against obesity. Dr. Davtyan and his team treat every patient individually and construct personalized treatment plans that fit their unique needs and goals. The center offers a wide spectrum of cutting-edge medical endoscopic, surgical, and minimally invasive weight loss procedures combined with exceptional compassion, empathy, and expertise to provide excellent outcomes for patients.

“The take-home message of this study indicates that people suffering from obesity can extend their lives and reduce their mortality, particularly from diabetes, cancer, and cardiovascular disease with the help of bariatric surgery (weight loss surgery),” says Dr. David Davtyan.

More about Dr. David Davtyan:

Dr. David G. Davtyan is a highly-respected weight loss surgeon with over 28 years of experience and has treated thousands of patients with exceptional results. He earned his medical degree from UCLA’s School of Medicine, where he was trained to treat extremely difficult and metastatic cancer cases. He went on to study bariatric surgery in Belgium, where the Lap-Band was first introduced and became one of the first surgeons in the United States to offer the procedure once it achieved FDA approval in April of 2001. Dr. Davtyan and his team offer top-quality weight loss surgery (bariatric surgery) and weight loss treatment in Los Angeles, Orange County, and the Inland Empire. For more information, please call 877-923-7546 or visit http://www.weightlosssurgeryla.com.

Share article on social media or email:

HealthyChildren.org Celebrates Spring With a 7-Day Sweepstakes Event


News Image

HealthyChildren.org Spring 2023 Sweepstakes Event

HealthyChildren.org, the official American Academy of Pediatrics (AAP) website for parents, celebrates the arrival of Spring by giving away seven $200 gift cards in the site’s 2023 Spring Sweepstakes event.Registered users of HealthyChildren.org may enter once each day during the event which runs March 27 through April 2, 2023. Winners will be drawn daily and announced on Facebook as they are confirmed. View the full contest rules.

About HealthyChildren.org

The only parenting website backed by 67,000 AAP member pediatricians, HealthyChildren.org offers trustworthy, up-to-the-minute health advice and guidance for parents and caregivers, along with interactive tools and personalized content. Registered users enjoy a customized home page as well as a free monthly e-newsletter. A new Ages & Stages program offers parents of young children (as well as those who are expecting a new baby) weekly texts and/or monthly emails based on the age(s) of their child(ren). The site also offers a Find a Pediatrician service, an Ask the Pediatrician tool, a KidsDoc Symptom Checker, and more than 5,000 articles in English and Spanish.

Share article on social media or email:

Autism Learning Partners launches Center-Based ABA Therapy for Individuals in Westerville, OH


“We’re excited to expand our Ohio center-based services offered in Cleveland to the Columbus area with individualized ABA services focused on building skills in socially significant areas through engaging interactions with peers,” said Rachael Schneider, M.A., BCBA-LBA, Executive Director at ALP.

ALP strives to give hope, support, and paths of progress for children and their families living with autism and related disorders. With their robust network of community partnerships and ever-growing list of accepted insurances, families can receive quality support. ALP believes a tailored, comprehensive care plan with a dedicated clinical team allows children and their family units to experience the most progress possible.

“We are excited to expand our Ohio center-based services offered in Cleveland to the Columbus area! We offer individualized ABA services in our uniquely designed center. We focus on building skills in socially significant areas through engaging interactions with peers that includes gross motor areas, sensory areas, and much more!,” said Rachael Schneider, M.A., BCBA-LBA, Executive Director at ALP. “Our centers offer increased resources, school readiness skills, generalization, a consistent clinical team, social opportunities and caregiver collaboration.”

ALP is a national leader in the special needs field since 1988. Headquartered in Monrovia, CA, they employ over 300 Board Certified Behavior Analysts (“BCBAs”) and have a total workforce of 3,400 nationwide, including Behavior Technicians providing home and center-based Applied Behavior Analysis (ABA) therapies. Services include: ABA care, as well as speech, occupational, physical therapies, and diagnostic services in select regions. ALP now offers treatment in 17 states including California, Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Rhode Island, Texas, Utah, and Virginia.

To learn more about Autism Learning Partners and its services, please visit http://www.AutismLearningPartners.com.

Share article on social media or email:

New Behavioral Health Business Outlook Report Shows Providers Ready to Expand Care Services and Revenue Opportunities Despite Staff-Driven Financial Strain


Behavioral Health Business, an Aging Media publication, has released the results of its 2023 Behavioral Health Outlook Survey and Report, identifying the top challenges and opportunities for providers of behavioral, mental health and substance use services. Participants expressed an overall optimism around referral growth opportunities, even while nearly 80% indicated the coming financial strain of health care’s staffing crisis.

To help solve that crisis, providers indicate a continued rise in their utilization of technology tools, starting with telehealth. They view a fairly even spread of growth opportunities in the industry for 2023, split between treating underserved populations, pursuing value-based relationships and expanding service offerings. Also evenly spread across online and internet searches, community referrals and physician offices.

Behavioral Health Business conducted the survey to learn how providers are navigating the difficult road to recovery and growth in a post-pandemic future. The results show the views of 150 professionals who identify as working for organizations that provide treatment for behavioral health, mental health and substance use disorders, painting a vivid picture of the industry-wide sentiment for the year to come.

In summary, respondents indicated:


  • Growth opportunities abound in behavioral health — Providers expect to see the greatest growth in partnerships during 2023, citing online and internet searches (27% of respondents), community referrals (27%) and physician offices (22%) as the greatest anticipated referral growth sources.
  • An overwhelming majority indicate staffing-related financial strain in 2023 — Seventy-seven percent of respondents indicated that staffing changes will also be the greatest area of financial strain in the behavioral health industry for 2023. More than half of respondents cited staffing as the industry’s biggest current challenge.
  • Providers are focused on value and accessibility while investors key in on mental health — Treating underserved populations (27% of respondents), pursuing value-based relationships (26%) and expanding service offerings (23%) are the top three opportunities in behavioral health for the year ahead, with mental health representing the most attractive investment target in behavioral health.
  • Telehealth use for behavioral health care will rise in 2023 — When it comes to digital health care tools, more than half of survey participants are most excited about telehealth in 2023. Thirty-eight percent of respondents believe telehealth use in behavioral health will increase relative to 2022.

“Day by day, care providers are seeing the opportunity to get behavioral and mental health services to more Americans through a combination of technology deployment and community and hospital partnerships,” said Behavioral Health Business Editor Laura Lovett. “The rising interest in investing in mental health care reveals just how vital this industry is today.”

The survey was conducted online between November 14, 2022, and December 26, 2022. Access the full survey results here.

About Aging Media Network and Behavioral Health Business

Aging Media Network, an innovative publishing company based in Chicago, Illinois, is the publisher of Behavioral Health Business, Senior Housing News, Home Health Care News, Skilled Nursing News and Hospice News. Behavioral Health Business is the leading source for news and information covering the industries of behavioral and mental health care.

Share article on social media or email:

Novita Pharmaceuticals Appoints Alan Wills as Its Chief Executive Officer


Novita Pharmaceuticals, Inc. (“Novita” or the “Company”), a privately held clinical-stage pharmaceutical company dedicated to developing novel cancer drugs based on its proprietary fascin inhibitor technology, today announced that the Company’s Board of Directors has appointed Alan Wills as its Chief Executive Officer.

Mr. Wills joined Novita as Chief Executive Officer on February 6, 2023, bringing extensive experience in the global biopharmaceutical industry, notably in business development, corporate strategy, M&A and licensing, and alliance management. Prior to joining Novita. Mr. Wills was Executive Vice President, Strategy & Business Development, at CSL Group. He previously served in a range of progressively senior level roles in Corporate Strategy, Business Development, Global Marketing and Portfolio Management at Pfizer, Bristol-Myers Squibb, and Auxilium Pharmaceuticals. In his earlier career, he worked at the Boston Consulting Group, Lucile Packard Children’s Hospital at Stanford, and United Healthcare. He holds a Master of Business Administration from Harvard Business School.

“Alan is a seasoned pharmaceutical senior executive and a strong strategic thinker and executer,” said Dr. Xin-Yun Huang, Chairman of the Board and a co-founder of Novita. “He brings a depth of business experience and acumen that will be a perfect complement to Novita’s founding team.”

“We are delighted to have recruited a talent like Alan,” said Dr. Jillian Zhang, President and Chief Scientific Officer, and a co-founder of Novita. “Our Company’s first-in-class fascin inhibitor NP-G2-044 is in the midst of a phase 2 clinical study. It is great timing for Alan to join us at this stage as we continue to advance the development of NP-G2-044 as a breakthrough cancer therapy.”

“It’s an exciting time to join Novita, with the Company’s lead compound moving through its phase 2 program and generating solid early data,” said Mr. Wills. “I look forward to helping Novita advance the development of new and innovative cancer therapies that will address critical unmet medical needs.”

About Novita Pharmaceuticals, Inc.

Novita Pharmaceuticals, Inc. (“Novita” or the “Company”) is a privately held clinical-stage biopharmaceutical company dedicated to developing ground-breaking drugs based on its proprietary fascin inhibitor technology to prevent and treat cancer metastasis and at the same time to boost anti-cancer immune responses. Cancer metastasis is the primary cause of over 90% of deaths of cancer patients and yet there is no drug specifically and directly targeting metastasis on the market today. In addition, while Immuno-Oncology (IO) with anti-PD-1 immune checkpoint inhibitors has made a significant impact on the treatment of many types of cancer, most cancer patients do not respond to current IO treatments. Novita aims to address both these important medical needs by developing inhibitors of fascin, a key protein critically involved in tumor cell motility and highly expressed in tumor cells and in antigen-presenting cells in the tumor tissues. The Company’s lead asset, a small-molecule fascin inhibitor NP-G2-044 has been shown in preclinical studies to block tumor cell migration, invasion, and metastasis. In animal models, NP-G2-044 in combination with immune checkpoint inhibitors demonstrated synergistic efficacy that tripled overall survival rates in comparison to IO alone. The multicenter Phase 2 clinical trial of NP-G2-044 titled “NP-G2-044 as Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies” is currently ongoing and open for patient enrollment.

For more clinical trial information, please go to:

https://clinicaltrials.gov/ct2/show/NCT05023486

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These statements are based on a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company’s control, and reflect future business decisions, which are subject to change. Among those factors that could cause actual results to differ materially from those described in the forward-looking statements are the risks associated with the Company’s being a development stage company with uncertain revenue streams; uncertain results or outcomes during clinical trials; certain rights owned by others over the Company’s intellectual property; failure to raise necessary capital in the future; the loss of key personnel; competition from other larger, better-capitalized peers; the Company’s reliance on incorrect assumptions regarding the market for its products, the costs of developing, manufacturing and marketing the Company’s products, and the timing and receipt of regulatory approval for the Company’s products; adverse economic conditions; and other risks. In light of the significant uncertainties inherent in the forward-looking statements, the inclusion of any such statement should not be regarded as a representation by Novita or any other person that the Company’s objectives or plans will be achieved.

Contact Info:

Christy Shue

cshue@novita-pharm.com

Share article on social media or email:

Gaize announces the launch of their real-time impairment screening device for cannabis and other drugs


Gaize being used at construction site

“Gaize was created to solve the problem of cannabis and drug impaired drivers and safety-sensitive workers. It’s a rapid screening tool that’s portable, non-invasive, and based on eye-movement tests with a long history of successful use.” – Ken Fichtler, Gaize Founder and CEO

Today, Gaize announced the launch of their real-time impairment screening device. The product is a first-of-its-kind fully automated, non-invasive and portable eye movement test. It combines well-established Drug Recognition Expert (DRE) eye examinations with the latest in artificial intelligence. Drug Recognition Expert eye tests are widely considered the gold standard for impairment detection, with 40+ years of successful use, many scientific studies on their effectiveness, and court acceptance in all 50 states. Gaize runs these same tests, exactly according to the DRE training manual, using a VR headset with embedded eye tracking sensors. The resulting data is then analyzed by machine learning models to discover involuntary eye movement changes which are correlated with impairment. This product launch comes following a recently completed clinical trial using the Gaize product, which was the largest in the world to ever investigate cannabis impairment.

Ken Fichtler, Gaize Founder and CEO said: “I created Gaize to solve the problem of cannabis impaired drivers and workers. THC behaves markedly differently in the body than does alcohol, and it can linger in the body for over a month since the last use. No amount of THC in the body has never been shown to produce a predictable level of impairment, so simply measuring THC is not indicative of impairment. Particularly in places where cannabis is legal, what we really care about is whether or not someone is impaired, not if they’ve used cannabis previously.”The results of the test are easy to interpret and each test is also backed by video evidence of the eye movement. From this, Gaize customers can easily and confidently make defensible decisions. Results are delivered in just 6 minutes from the time the test is started, enabling much more frequent impairment screening.

Fichtler said, “We envision a world where drivers and workers are verifiably sober before engaging in any safety sensitive task. With Gaize, companies can test employees each day before the start of shift, after a lunch break, or before operating equipment.”Fichtler ended by saying “We’ve had our heads down following the science and building this product for over two years. To have it come to market today feels great. It’s going to be truly revolutionary for maintaining safe roads and workplaces with fewer preventable impairment related deaths and injuries.”

The product is available to commercial customers starting today. To learn more, visit http://www.gaize.ai.

Members of the Press are encouraged to contact support@gaize.ai.

Share article on social media or email:

The GHT Companies to Showcase its Manufacturing Capabilities and Retail Lines at Natural Products Expo West 2023


The GHT Companies Exhibiting at Expo West 2023

“We value this show because, as a recognized authority in contract manufacturing, productformulation, and sourcing for raw materials, we make some of our most valuableconnections and develop mutually beneficial business relationships during Expo West,”GHT Companies President & CEO Jim Rex.

The GHT Companies, a decades-long leader in the natural supplement formulation/manufacturing/market distribution space, has announced its attendance at Natural Products Expo West 2023 to showcase its start-to-finish product services – from access to exclusive raw ingredient discoveries with founding scientists from around the globe, product ideation, product formulation, and manufacturing through their acclaimed production company, Health Specialties Manufacturing, all the way to market distribution for private label lines or in one of their own established branded product lines: Vegan Life Nutrition, Global Health Trax, and Vibrant Nutraceuticals.

From March 9-11, The GHT Companies will be at Booth #3472 in Hall D of the Anaheim Convention Center to discuss partnership opportunities with:

● Retailers who are looking for products to improve their margins can explore vitamins and supplements from GHT’s three branded lines: Vegan Life Nutrition, Vibrant Nutraceuticals, and Global Health Trax.

● Private label lines in the market for highly-vetted and innovative raw ingredients and top quality formulation and manufacturing.

● Founding scientists in need of the highest-quality formulation and/or manufacturing partner to bring their product to life and to market.

“We value this show because, as a recognized authority in contract manufacturing, product formulation, and sourcing for raw materials, we make some of our most valuable connections and develop mutually beneficial business relationships during Expo West,” said GHT Companies President & CEO Jim Rex. “We’re looking forward to taking on new partnerships with companies in all stages of the product journey – whether they’re looking for quality ingredient sourcing, product formulation, manufacturing, complex packaging, or top-quality products to improve their retail margins, we’re ready to help them through it all,” Rex added.

GHT offers impressive manufacturing capabilities such as complex powder blending, cold-fill liquids, and supplement encapsulation, and heralds its “Three Zeros”:

● Zero “minimum order” requirements: GHT handles both large and small order quantities.

● Zero product recalls: Even after decades of business, GHT has never had a formal recall on any of the products they have manufactured.

● Zero failed audits: GHT has proudly never failed a federal, state, or third-party audit, and they maintain over nine industry certifications.

In addition to GHT’s contract manufacturing services, the company will also be showcasing its three branded supplement lines (Vegan Life Nutrition, Global Health Trax, and Vibrant Nutraceuticals), each of which features products containing exclusive raw ingredients from partnerships with founding scientists from around the world.

At the show, retailers and customers alike will be able to sample some of these brands’ newest and most innovative products, including probiotics, spray vitamins, and even chewing gums that provide seasonal support.

You can schedule a meeting with GHT before or during Natural Products Expo West 2023 on their website.

About The GHT Companies

The GHT Companies is a collection of four specific operational business units that work together to translate scientific discovery into business enterprise. From the research and development of cutting-edge ingredients and product formulation and testing to manufacturing and distribution, GHT is a complete resource for taking high-quality products to commercial markets worldwide.

Our partnership starts from the beginning of the product cycle: we vet, champion, and continuously support top scientists who have discovered new ingredients for nutritional supplements and vitamins. With our extensive network of resources, we provide a clear pathway to bring these discoveries to market and into the hands of consumers. We have access to the manufacturing, packaging, marketing and distribution systems needed to turn formulations into sought-after products. GHT’s consumer-facing brands act as vehicles for introducing new discoveries to consumers and making them available for purchase.

Next, we partner with private label companies that seek superior, reliable products that provide both quality and consistency. We continuously research, source, and manufacture new products so partnering companies have access to the most exciting products available. As we continue to develop new products, our private label partners can consistently add innovative and cutting-edge products to their lines.

With years of experience and devotion to finding new formulations, we are the industry leader in providing the most reliable raw ingredients on the market. Our manufacturing partners feel at ease knowing that we maintain the highest standards, supplying safe and compliant ingredients that reflect the integrity of their brands.

Media Contact:

Marketing Department, request Shanna Denfeld, Vice-President

(760) 542-3000

marketing@theghtcompanies.com

Share article on social media or email:

The Fenway Institute and NORC


Rectangular blue Fenway Health logo, blue background with white text

This is the first analysis to our knowledge to document the elevated prevalence of kidney disease among older adults in the U.S. who are lesbian, gay, bisexual, or a sexual orientation other than heterosexual.

According to a new study by researchers from NORC at the University of Chicago, The Fenway Institute, and the Centers for Medicare & Medicaid Services (CMS), sexual minority (LGBT+) men and women over age 50 are more likely to have kidney disease compared to their heterosexual peers.

The study, published online in the Journal of the American Society of Nephrology, found that 6.23 percent of older sexual minority men had kidney disease compared to 4.81 percent of heterosexual men, while 5.97 percent of older sexual minority women reported a kidney disease diagnosis compared with 4.88 percent of heterosexual women. In addition, the study found a higher incidence of risk factors for kidney disease—smoking, activity limitations, adverse health outcomes, and limited access to health care, housing, and employment—among older LGBT+ people.

“This is the first analysis to our knowledge to document the elevated prevalence of kidney disease among older adults in the U.S. who are lesbian, gay, bisexual, or a sexual orientation other than heterosexual,” said Sean Cahill, coauthor and director of Health Policy Research at the Fenway Institute. “Even after adjusting for demographics and risk factors, older gay and bisexual men were nearly twice as likely as older heterosexual men to report a kidney disease diagnosis.”

Despite well-documented disparities in chronic kidney disease risk factors such as diabetes and hypertension in LGBT+ adults, there have been limited studies examining kidney disease prevalence in this population.

“These results support increasing access to screening for kidney disease risk factors in this population, providing culturally responsive care, and addressing societal drivers of vulnerability in older LGBT+ adults,” added Mollie Hertel, coauthor and senior research scientist at NORC.

Study results were developed using data from the Behavioral Risk Factor Surveillance System (BRFSS). The BRFSS introduced sexual orientation and gender identity questions in 2014. NORC analyzed BRFSS data from 2014 to 2019 to determine self-reported kidney disease prevalence in LGBT+ older adults (50+) compared to their heterosexual peers.

“This research suggests that national surveys such as the BRFSS should work toward developing standardized, consistent, and tested kidney disease nomenclature to ensure it captures an accurate estimate of kidney disease prevalence for future surveillance efforts,” said Meghana Chandra, coauthor and research scientist at NORC.

The study is scheduled to be published in print versions of the journal later this year.

Share article on social media or email: